Cognizant
CTSH
$45.97
-3.69%
Cognizant Technology Solutions is a multinational IT services and consulting provider, operating in the Information Technology Services industry, offering a range of digital transformation, consulting, and business process outsourcing services to enterprise clients globally. The company is a major player in the global IT services landscape, leveraging a significant offshore workforce, particularly in India, to deliver cost-effective solutions, with distinct strengths in key verticals like Financial Services and Healthcare. The current investor narrative is dominated by a significant stock price decline, reflecting concerns over growth deceleration and margin pressures, as evidenced by recent quarterly results and a sharp technical breakdown, placing the company in a potential value or turnaround debate.…
CTSH
Cognizant
$45.97
Investment Opinion: Should I buy CTSH Today?
Rating: Hold. The core thesis is that while CTSH appears deeply undervalued on a forward earnings basis, the severe fundamental deterioration and lack of positive momentum warrant caution, making it a 'show me' story rather than a clear buy.
Supporting this Hold rating are several conflicting data points: the compelling forward P/E of 8.52x and EV/Sales of 1.15x suggest deep value, and analyst EPS forecasts imply massive growth. However, these are countered by the alarming 4.0 percentage point year-over-year gross margin compression, the sequential revenue decline in Q4, and the catastrophic -36.11% three-month price return. The stock trades at a discount to its own historical P/E (17.9x trailing vs. historically >20x), but this discount is justified by the deteriorating fundamentals.
The thesis would upgrade to a Buy on concrete evidence of margin stabilization (gross margin holding above 32%) and a return to sequential revenue growth, which would validate the forward earnings estimates. It would downgrade to a Sell if gross margins fall below 30% or if revenue growth turns negative year-over-year, confirming a structural decline. Currently, the stock is fairly valued relative to its near-term challenges but undervalued if management can execute a turnaround.
Sign up to view all
CTSH 12-Month Price Forecast
CTSH presents a classic value vs. value trap dilemma. The valuation is undeniably cheap, but the fundamental trends are undeniably poor. The neutral stance reflects the high uncertainty around whether management can halt the margin erosion. The stance would upgrade to bullish on confirmation of margin stabilization for two consecutive quarters, as this would de-risk the earnings forecast. It would turn bearish if margins break below 30%, signaling the competitive threat is structural rather than cyclical. The base case of a muted recovery is most likely, but the asymmetric risk/reward is noteworthy for deep-value investors with a high risk tolerance.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cognizant's 12-month outlook, with a consensus price target around $59.76 and implied upside of +30.0% versus the current price.
Average Target
$59.76
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$37 - $60
Analyst target range
The stock is covered by 15 analysts, and the institutional ratings show a mix of Hold/Neutral/Sector Perform ratings from firms like TD Cowen, RBC Capital, and Morgan Stanley, alongside some Buy/Overweight ratings from Guggenheim and Wells Fargo, indicating a consensus that leans neutral-to-cautiously optimistic. The average revenue estimate for the next period is $24.74 billion, with an EPS estimate of $6.26, but explicit price targets are not provided in the data; the wide range of recent analyst actions (from Hold to Outperform) and the significant stock price decline since many of those ratings were issued suggest targets are likely under review, and the wide target spread typical of such situations signals high uncertainty around the company's near-term prospects and appropriate valuation.
Bulls vs Bears: CTSH Investment Factors
The evidence currently favors the bear case, as the severe price decline, deteriorating fundamentals (growth deceleration, margin compression), and negative momentum are concrete and recent. The bull case rests heavily on a deep-value valuation and a projected earnings recovery that is not yet visible in reported results. The single most important tension in the investment debate is whether the current forward P/E of 8.5x correctly anticipates a permanent degradation of Cognizant's business model, or if it represents a profound mispricing that will correct as the company stabilizes its margins and returns to modest growth. The resolution of this tension depends entirely on the trajectory of gross margins and revenue growth over the next two quarters.
Bullish
- Deep Value Forward P/E of 8.5x: The forward P/E of 8.52x is exceptionally low for a profitable IT services company, implying the market has priced in extremely pessimistic growth. This represents a significant discount to its own historical trailing P/E of 17.9x and suggests substantial upside if earnings stabilize.
- Robust Balance Sheet & Cash Flow: The company has minimal financial risk with a low debt-to-equity ratio of 0.105 and a strong current ratio of 2.34. It generates substantial free cash flow ($2.595B TTM), funding a sustainable dividend (27.35% payout) and share buybacks, providing a margin of safety.
- Analyst EPS Growth Forecast of 11x: Analysts forecast forward EPS of $6.26, implying an 11-fold increase from the trailing twelve-month EPS of $0.056. This dramatic projected earnings recovery, if realized, would justify a much higher stock price from current depressed levels.
- Trading at 52-Week Low: The stock is trading at $52.43, just 0.3% above its 52-week low of $52.28. This extreme technical oversold condition, combined with a 30.31% annual decline, suggests most negative news may be priced in, creating a potential inflection point for value investors.
Bearish
- Severe Growth Deceleration & Margin Pressure: Q4 2025 revenue grew only 4.94% YoY and declined sequentially from Q3. More critically, gross margin compressed to 31.11% from 35.12% a year ago, indicating intense pricing competition and a deteriorating core business model.
- Catastrophic Price Momentum & Underperformance: The stock is down 36.11% over the past three months and 14.4% over the past month, underperforming the SPY by 40.25 and 24.38 percentage points, respectively. This accelerating decline signals a fundamental breakdown and a lack of near-term catalysts.
- Volatile & Declining Profitability: Net income is highly volatile, dropping from $663M in Q1 2025 to $274M in Q3 2025 before recovering to $648M in Q4. This inconsistency, coupled with the gross margin trend, raises questions about earnings quality and future stability.
- Analyst Consensus Leans Neutral/Hold: With 15 analysts covering the stock, the consensus leans towards Hold/Neutral/Sector Perform ratings from major firms. The lack of strong bullish conviction, especially after the steep decline, suggests institutional skepticism about a near-term turnaround.
CTSH Technical Analysis
The prevailing price trend is a pronounced and sustained downtrend, with the stock down 30.31% over the past year, culminating in a close of $52.43 on May 1, 2026. The current price sits at the very bottom of its 52-week range, trading just 0.3% above its 52-week low of $52.28, which signals extreme bearish sentiment and positions the stock as a potential deep-value opportunity, albeit one that carries significant 'catching a falling knife' risk given the momentum. Recent short-term momentum is severely negative and accelerating the longer-term decline, with the stock down 14.4% over the past month and 36.11% over the past three months; this sharp deceleration, especially against a market (SPY) that was up 9.98% and 4.14% over the same periods, indicates severe company-specific underperformance and a lack of near-term catalysts to arrest the slide. Key technical support is clearly defined at the 52-week low of $52.28, with resistance far above at the 52-week high of $87.03; a sustained breakdown below $52.28 would signal a continuation of the bear trend, while any recovery would first need to reclaim the $60-$65 zone. The stock's beta of 0.976 suggests its volatility is roughly in line with the broader market, but the massive 40.25 percentage points of underperformance versus the SPY over three months highlights idiosyncratic risk currently dominating its price action.
Beta
0.80
0.80x market volatility
Max Drawdown
-47.0%
Largest decline past year
52-Week Range
$45-$87
Price range past year
Annual Return
-43.4%
Cumulative gain past year
| Period | CTSH Return | S&P 500 |
|---|---|---|
| 1m | -24.1% | +8.2% |
| 3m | -30.2% | +9.0% |
| 6m | -36.7% | +10.5% |
| 1y | -43.4% | +26.5% |
| ytd | -43.4% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTSH Fundamental Analysis
Revenue growth has decelerated and turned slightly negative on a sequential basis, with Q4 2025 revenue of $5.333 billion representing a modest 4.94% year-over-year increase but a decline from Q3's $5.415 billion; segment data shows Healthcare ($1.621B) and Financial Services ($1.586B) as the largest contributors, but the overall trajectory suggests a challenging demand environment for IT services. The company remains profitable with a Q4 net income of $648 million, but profitability is volatile, as evidenced by the sharp drop from Q3's $274 million (impacted by a high tax rate) and a gross margin of 31.11% in Q4, which has compressed from 33.86% in Q3 and 35.12% in the year-ago quarter, indicating pricing or mix pressure. The balance sheet is very healthy with a strong current ratio of 2.34 and minimal financial risk evidenced by a low debt-to-equity ratio of 0.105; the company generates substantial cash, with TTM free cash flow of $2.595 billion, providing ample liquidity to fund its dividend (payout ratio of 27.35%) and share repurchases while maintaining a robust financial position.
Quarterly Revenue
$5.3B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.31%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTSH Overvalued?
Given the positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 17.90x, while the forward P/E is significantly lower at 8.52x, indicating the market expects a substantial recovery in earnings, with forward estimates of $6.26 per share implying nearly 11x growth from the trailing twelve-month EPS of $0.056. Compared to sector averages, the stock trades at a discount on a sales basis with a PS ratio of 1.89x and an EV/Sales of 1.15x, though direct industry average comparisons are not provided in the data; the low forward P/E of 8.5x suggests the market is pricing in very subdued growth expectations relative to its historical profile. Historically, the current trailing P/E of 17.90x is below the multi-year range observed in the historical ratios data, which has frequently been above 20x, suggesting the stock is trading at a discount to its own history, which could indicate either a value opportunity or that the market anticipates a permanent degradation in its growth or profitability profile.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's deteriorating profitability profile and growth stagnation. The sequential decline in Q4 revenue and the sharp compression of gross margin from 35.12% to 31.11% year-over-year indicate significant operational headwinds, likely from competitive pricing pressure and unfavorable service mix. While the balance sheet is strong, the volatility in quarterly net income (e.g., $274M in Q3 to $648M in Q4) suggests earnings are subject to lumpy items, making future projections less reliable. The core risk is that margin pressure persists, preventing the substantial earnings rebound implied by the forward P/E.
Market & Competitive Risks are elevated due to the stock's massive underperformance and valuation compression. The stock has underperformed the SPY by over 40 percentage points in three months, indicating severe company-specific de-rating. Trading near its 52-week low, the risk of further multiple compression is lower, but the sector faces threats from automation, in-sourcing, and competition from lower-cost global IT providers. The stock's beta of 0.976 suggests it is not a defensive shelter during market downturns, and its current narrative as a 'value trap' could prolong institutional selling.
Worst-Case Scenario involves a continuation of the current negative trends: gross margins fail to stabilize and decline further, revenue growth turns negative year-over-year, and the projected EPS of $6.26 is missed significantly. This would lead to a re-rating to an even lower multiple, potentially testing levels seen during prior crises. Given the 52-week low is $52.28 and the stock has already experienced a max drawdown of -39.53%, a realistic further downside in an adverse scenario could be an additional 15-20%, targeting the mid-$40s, representing a potential loss of -20% to -25% from the current $52.43 price.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Continued gross margin compression, which fell 400 bps year-over-year to 31.11%, threatening profitability. 2) Growth Risk: Revenue growth deceleration to 4.94% YoY and sequential decline, indicating weak demand. 3) Sentiment/Momentum Risk: The stock is in a severe downtrend, down 36% in 3 months, which can become self-fulfilling. 4) Execution Risk: The company must deliver on analyst EPS forecasts of $6.26, which implies an 11x increase from trailing EPS—a very high bar.
Our 12-month forecast outlines three scenarios. The Base Case (55% probability) sees the stock recovering to $58-$65 as the company stabilizes, aligning with a forward P/E of ~9-10x on estimated EPS of $6.26. The Bull Case (25% probability) targets $70-$75 on successful margin improvement and multiple expansion. The Bear Case (20% probability) warns of a drop to $45-$52 if margins collapse further. The base case is most likely, assuming no further deterioration, but the wide range reflects high uncertainty. The key assumption is the stabilization of gross margins.
CTSH is statistically undervalued based on forward earnings metrics. Its forward P/E of 8.52x is very low for a profitable technology company, and it trades at a discount to its own historical trailing P/E average (above 20x). The EV/Sales of 1.15x also suggests a cheap price relative to revenue. However, this undervaluation is justified by the market's expectation of poor future growth and profitability, as evidenced by the 30% stock price decline over the past year. The valuation implies the market expects a permanent degradation of its business model.
CTSH is a high-risk, high-potential-reward stock for a specific type of investor. At a forward P/E of 8.5x and trading at its 52-week low, it offers compelling value if the company can stabilize its business. However, it is not a 'good buy' for most investors due to the severe fundamental deterioration, including gross margin compression and slowing growth. It could be a good buy for deep-value, contrarian investors with a 2-3 year horizon who can tolerate further downside. The biggest risk is that the cheap valuation gets even cheaper if margins continue to fall.
CTSH is unsuitable for short-term trading due to its high volatility, negative momentum, and lack of near-term catalysts. It is a candidate for long-term investment only for patient, value-oriented investors. The turnaround required to justify a higher valuation will take multiple quarters, if not years, to materialize. Given the need to see several earnings reports to confirm a trend change, a minimum holding period of 18-24 months is suggested. The 1.5% dividend yield is too low to justify an income-oriented strategy.